Tesamorelin ���景与作用机制 — Complete Guide

By Editorial Desk · published 2026-02-22 · last reviewed 2026-04-05 · News

垂体受体 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-04-05. Where a claim depends on a specific study, the study is described rather than over-claimed.

tesamorelin 背景与作用机制

研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。

tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。

Background and Clinical Profile

Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.

Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.

Tesamorelin at a glance

Background and Clinical Development

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Related pages on this site

• Modern overview
• Lightweight trends
• Smart report
• Scalable digest
• Verified reference
• Optimized workbook
• Regional casebook
• Adaptive update

Reference notes

Inoculation and fermentation: Skimmed milk is pumped into enclosed vats and heated to approximately 30–32 °C (86–90 °F). A mesophilic starter culture of lactic acid-producing strains (such as Lactococcus lactis ssp. lactis or L. lactis ssp. cremoris) is introduced. These bacteria ferment the milk's lactose into lactic acid, dropping the pH over 4 to 8 hours. Coagulation: A precise dose of microbial or animal rennet is added to facilitate protein cross-linking. The rising acidity and the rennet cause the milk to curdle into a uniform, gelatinous mass. Cutting and cooking: Internal wire grids slice the gel into uniform cubes, determining whether the batch is classified as "small-curd" (<4 mm) or "large-curd" (>8 mm). The vats are heated to 49–54 °C (120–130 °F) under gentle agitation, causing the curd to contract and expel liquid whey. Washing and dressing: The whey is drained, and the curd mass is flooded with chilled, purified water. This stops further bacterial acidification and rinses away excess lactic acid, resulting in a mild flavour profile. The dry curds are then mechanically blended with a pasteurised cream dressing and salt.

In 1947, David Lester and Leon Greenberg found strong evidence that paracetamol was a major metabolite of acetanilide in human blood, and in a subsequent study, they reported that large doses of paracetamol given to albino rats did not cause methemoglobinemia. In 1948, Bernard Brodie, Julius Axelrod and Frederick Flinn confirmed that paracetamol was the major metabolite of acetanilide in humans, and established that it was just as efficacious an analgesic as its precursor. They also suggested that methemoglobinemia is produced in humans mainly by another metabolite, phenylhydroxylamine. A follow-up paper by Brodie and Axelrod in 1949 established that phenacetin was also metabolized to paracetamol. This led to a "rediscovery" of paracetamol. Paracetamol was first marketed in the United States in 1950 under the name Trigesic, a combination of paracetamol, aspirin, and caffeine. Reports in 1951 of three users stricken with the blood disease agranulocytosis led to its removal from the marketplace, and it took several years until it became clear that the disease was unconnected. The following year, 1952, paracetamol returned to the U.S. market as a prescription drug. In the United Kingdom, marketing of paracetamol began in 1956 by Sterling-Winthrop Co. as Panadol, available only by prescription, and promoted as preferable to aspirin since it was safe for children and people with ulcers.

An exopeptidase is any peptidase that catalyzes the cleavage of the terminal (or the penultimate) peptide bond; the process releases a single amino acid, dipeptide or a tripeptide from the peptide chain. Depending on whether the amino acid is released from the amino or the carboxy terminal (N-terminus or C-terminus), an exopeptidase is further classified as an aminopeptidase or a carboxypeptidase, respectively. Thus, an aminopeptidase, an enzyme in the brush border of the small intestine, will cleave a single amino acid from the amino terminus, whereas carboxypeptidase, which is a digestive enzyme present in pancreatic juice, will cleave a single amino acid from the carboxylic end of the peptide. Some examples of exopeptidases include:

North Korea's human rights record is often considered to be the worst in the world and has been globally condemned, with the United Nations, the European Union and groups such as Human Rights Watch all critical of the country's record. Furthermore, North Korea has the highest estimated prevalence of modern slavery in the world. . As of 2021, a Global Slavery Index 2023 report estimates that about one-in-ten people live in modern slavery conditions. Forms of torture, forced labour, and abuses are all widespread. Most international human rights organizations consider North Korea to have no contemporary parallel with respect to violations of liberty.

According to the author of the study there were 137 such events in Thailand during this period. Other ASEAN nations ranked in the study were Myanmar, ranked 3; Philippines, 5; and Vietnam, 8. Climate Change Performance Index (CCPI) 2017: Of 58 nations responsible for about 90% of global energy-related CO2 emissions, Thailand was ranked 42d in taking "action on climate protection" (1=best, 61=worst), earning an assessment of "poor". Other ASEAN nations ranked were Indonesia, 22 "good"; Malaysia, 44, "poor"; and Singapore, 54, "very poor". Global Climate Risk Index 2017: Thailand ranked number 10 of 180 nations most affected by "...weather-related loss events..." during the period 1996-2015 (1=most affected, 180=least affected) according to Germanwatch. Other ASEAN nations ranked in the top 10 were Myanmar, 2; Philippines, 5; and Vietnam, 8. Climate Central: Thailand is ranked seventh (higher number=lower risk) on the "Top 20 Most At-Risk Countries" for exposure to sea level rise and coastal flooding. It estimates the number of "People living on land that will be below sea level or chronic flood levels by the end of the century, assuming current emissions trends continue, and medium sensitivity of sea level to warming." In Thailand, eight million persons, or 12% of the population, are "at-risk" according to the study. Six of ASEAN's ten member-states are on the at-risk list. Climate Change Performance Index 2016: Thailand ranked 49 of 61 (1=best, 61=worst) countries, putting it in the "Very Poor" performance category.

Sources: en.wikipedia.org

Reference notes

The neck of the emu is pale blue and shows through its sparse feathers. They have grey-brown plumage of shaggy appearance; the shafts and the tips of the feathers are black. Solar radiation is absorbed by the tips, and the inner plumage insulates the skin. This prevents the birds from overheating, allowing them to be active during the heat of the day. A unique feature of the emu feather is the double rachis emerging from a single shaft. Both of the rachis have the same length, and the texture is variable; the area near the skin is rather furry, but the more distant ends resemble grass. The sexes are similar in appearance, although the male's penis can become visible when he urinates and defecates. The plumage varies in colour due to environmental factors, giving the bird a natural camouflage. Feathers of emus in more arid areas with red soils have a rufous tint while birds residing in damp conditions are generally darker in hue. The juvenile plumage develops at about three months and is blackish finely barred with brown, with the head and neck being especially dark. The facial feathers gradually thin to expose the bluish skin. The adult plumage has developed by about fifteen months. The eyes of an emu are protected by nictitating membranes. These are translucent, secondary eyelids that move horizontally from the inside edge of the eye to the outside edge. They function as visors to protect the eyes from the dust that is prevalent in windy arid regions. Emus have a tracheal pouch, which becomes more prominent during the mating season.

=== Flavodoxin-1 domain === Flavoproteins are ubiquitous biocatalysts binding specific redox active prosthetic groups. The domain is associated with electron transfer proteins and used in electron transport systems. The cofactor flavin-mononucleotide (FMN) is bound non-covalently to the domain, which is functionally interchangeable with iron-sulfur constituted proteins regulating electron transfer or ferredoxins.

SumoPred-PLM or SUMOylation site Prediction using Protein Language Model - An AI deep learning utility to predict based on known biological rules around SUMO2 and SUMO3 binding in human proteins incorporating knowledge from a separate pretrained PLM tool developed previously in 2021 by Elnaggar et al. known as ProtT5-XL-UniRef50. Such collaboration between multidisciplinary AI tools is becoming common practice.

== Intellectual property == A2 Corporation licensed patents filed in the 1990s by the New Zealand Dairy Board and filed its own patents on genetic tests to determine what form of beta-casein cows produce in milk and concerning potential adverse health consequences of standard milk. By 2012 A2 Corporation had developed a worldwide suite of intellectual property, including trademarks, trade secrets, and patents covering products, the genetic test and methods to develop A1 protein-free producing herds, as well as methods to check the protein content and fatty acid content of milk, dietary supplements with A2 beta-casein, and even therapeutic uses of A1 protein-free products. The a2 Milk Company continues to develop a portfolio of intellectual property, including trademarks and patents. The a2 Milk Company also invests in targeted research and development associated with the benefits of the A2 protein. In September 2017, it was reported that the a2 Milk Company got approval to keep selling its products in China.

Sources: en.wikipedia.org

Notes from published material

=== Liver transplant === In people who develop acute liver failure or who are otherwise expected to die from liver failure, the mainstay of management is liver transplantation. Liver transplants are performed in specialist centers. The most commonly used criteria for liver transplant were developed by physicians at King's College Hospital in London. Patients are recommended for transplant if they have an arterial blood pH less than 7.3 after fluid resuscitation or if a patient has Grade III or IV encephalopathy, a prothrombin time greater than 100 seconds, and a serum creatinine greater than 300 mmol/L In a 24-hour period. Other forms of liver support have been used including partial liver transplants. These techniques have the advantage of supporting the patient while their own liver regenerates. Once liver function returns immunosuppressive drugs are commenced and they have to take immunosuppressive medication for the rest of their lives.

Alkylating agents are the oldest group of chemotherapeutics in use today. Originally derived from mustard gas used in World War I, there are now many types of alkylating agents in use. They are so named because of their ability to alkylate many molecules, including proteins, RNA and DNA. This ability to bind covalently to DNA via their alkyl group is the primary cause for their anti-cancer effects. DNA is made of two strands and the molecules may either bind twice to one strand of DNA (intrastrand crosslink) or may bind once to both strands (interstrand crosslink). If the cell tries to replicate crosslinked DNA during cell division, or tries to repair it, the DNA strands can break. This leads to a form of programmed cell death called apoptosis. Alkylating agents will work at any point in the cell cycle and thus are known as cell cycle-independent drugs. For this reason, the effect on the cell is dose dependent; the fraction of cells that die is directly proportional to the dose of drug. The subtypes of alkylating agents are the nitrogen mustards, nitrosoureas, tetrazines, aziridines, cisplatins and derivatives, and non-classical alkylating agents. Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas include N-Nitroso-N-methylurea (NMU), carmustine (BCNU), lomustine (CCNU) and semustine (MeCCNU), fotemustine and streptozotocin (STZ). Tetrazines include dacarbazine, mitozolomide and temozolomide. Aziridines include thiotepa, mitomycin and diaziquone (AZQ).

=== In the digestive system === In the digestive system, VIP seems to induce smooth muscle relaxation (lower esophageal sphincter, stomach, gallbladder), stimulate secretion of water into pancreatic juice and bile, and cause inhibition of gastric acid secretion and absorption from the intestinal lumen. Its role in the intestine is to greatly stimulate secretion of water and electrolytes, as well as relaxation of enteric smooth muscle, dilating peripheral blood vessels, stimulating pancreatic bicarbonate secretion, and inhibiting gastrin-stimulated gastric acid secretion. These effects work together to increase motility. It also has the function of stimulating pepsinogen secretion by chief cells. VIP seems to be an important neuropeptide during inflammatory bowel diseases since the communication between mast cells and VIP in colitis, as in Crohn's disease, is upregulated.

Sources: en.wikipedia.org

Frequently asked questions